Immune reconstitution at 12 months can predict superior overall survival in reduced intensity alemtuzumab based conditioning transplant recipients for high risk MDS and AML ; a single centre experience
Kanellopoulos, A. Saeed, M. Kaparou, M. Eden, D. Khawaja, J. Cain, L. Qureshi, I. Xenou, E. Lee, S. Randall, K.
Kanellopoulos, A.
Saeed, M.
Kaparou, M.
Eden, D.
Khawaja, J.
Cain, L.
Qureshi, I.
Xenou, E.
Lee, S.
Randall, K.
Citations
Altmetric:
Affiliation
Heart of England NHS Trust; New Cross Hospital, Wolverhampton; South Warwickshire University NHS Foundation Trust
Other Contributors
Publication date
2016-03-21
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Physicians Poster Sessions abstract P245 of the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, Valencia, Spain, 3–6 April 2016.
Citation
Kanellopoulos A, Saeed M, Kaparou M, Eden D, Khawaja J, Cain L, Qureshi I, Xenou E, Lee S, Randall K, Arbuthnot C, Borg A, Holder K, Bratby L, Kishore B, Lovell R, Paneesha S, Nikolousis E. Immune reconstitution at 12 months can predict superior overall survival in reduced intensity alemtuzumab based conditioning transplant recipients for high risk MDS and AML; a single centre experience. Bone Marrow Transplant. 2016 Mar;51(Suppl 1):S242. doi: 10.1038/bmt.2016.48.
Type
Conference Output